Seelos Therapeutics Inc. Stock News

Amalgamated Bank bought a new position in Seelos Therapeutics, Inc. (NASDAQ:SEEL) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 14,317 shares of the companys stock, valued at approximately $38,000. Several other large investors have also recently made changes to their positions in SEEL. BlackRock Inc. increased its position in Seelos Therapeutics by []

Seelos Therapeutics, Inc. (SEEL) with the stream of -3.72% also noticed, India Morgan Stanley (MS) encountered a rapid change of -0.54% in the last hour of Wednesdays trading session. Seelos The post Explosive Stock: Seelos Therapeutics, Inc. (NASDAQ:SEEL), Morgan Stanley (NYSE:MS) appeared first on Stocks Equity .

WASHINGTON (dpa-AFX) - Clinical-stage biopharmaceutical company Seelos Therapeutics, Inc. (SEEL), on Wednesday announced the placement of a $22 million senior secured convertible note and shares o

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a

iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc (NASDAQ: SEEL ). Seelos will have exclusive worldwide rights for Wafermine, except China, including Hong Kong, Macau, and Taiwan - for which iX Biopharma will retain the rights. Seelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine Full story available on Benzinga.com

Cubist Systematic Strategies LLC raised its stake in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 201.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,000 shares of the companys stock after purchasing an additional 107,000 shares during the []

In todays recent session, 2.36 million shares of the Seelos Therapeutics Inc. (NASDAQ:SEEL) have been traded, and its beta is 2.75. Most recently the companys share price was $1.75, and it changed around -$0.16 or -8.64% from the last close, which brings the market valuation of the company to $198.60M. SEEL at last check was An Analysis Of Seelos Therapeutics Inc. (NASDAQ: SEEL), And Its Business Forecast Read More »

The Global Psychedelic Medicine Market report offers a comprehensive evaluation of the market. It does give in-depth analysis via qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven

Boothbay Fund Management LLC trimmed its holdings in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 61.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,385 shares of the companys stock after selling 52,306 shares during the period. Boothbay Fund Management LLCs []

10 penny stocks to watch this week. The post 10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

The FDA has accepted Seelos Therapeutics Inc's (NASDAQ: SEEL) Investigation New Drug application to study SLS-005 (trehalose injection, 90.5 mg/mL) for spinocerebellar Ataxia (SCA).  The FDA has a

Why investors are watching these biotech penny stocks right now The post 3 Biotech Penny Stocks to Watch That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information